5P Strategies for Management of Multiple Endocrine Neoplasia Type 2: A Paradigm of Precision Medicine

Autor: Xiao-Ping Qi, Mujin Ye, Chenming Xu, Shuyuan Li, Yi-Qiang Ding, You-Liang Si
Rok vydání: 2020
Předmět:
5P strategies
0301 basic medicine
Oncology
multiple endocrine neoplasia type 2
medicine.medical_specialty
precision medicine
Endocrinology
Diabetes and Metabolism

Multiple Endocrine Neoplasia Type 2a
030209 endocrinology & metabolism
Prenatal diagnosis
Multiple endocrine neoplasia type 2
Review
RET proto-oncogene
Proto-Oncogene Mas
lcsh:Diseases of the endocrine glands. Clinical endocrinology
Pheochromocytoma
03 medical and health sciences
Endocrinology
0302 clinical medicine
Germline mutation
medullary thyroid carcinoma
Internal medicine
medicine
Humans
Genetic Testing
Genetic testing
Hyperparathyroidism
lcsh:RC648-665
medicine.diagnostic_test
business.industry
Proto-Oncogene Proteins c-ret
Disease Management
medicine.disease
Precision medicine
pheochromocytoma
030104 developmental biology
business
Zdroj: Frontiers in Endocrinology, Vol 11 (2020)
Frontiers in Endocrinology
ISSN: 1664-2392
DOI: 10.3389/fendo.2020.543246
Popis: Multiple endocrine neoplasia type 2 (MEN2) is a neuroendocrine cancer syndrome characterized by medullary thyroid carcinoma, in combination or not with pheochromocytoma, hyperparathyroidism, and extra-endocrine features. MEN2 syndrome includes two clinically distinct forms subtyped as MEN2A and MEN2B. Nearly all MEN2 cases are caused by germline mutations of the RET proto-oncogene. In this review, we propose “5P” strategies for management of MEN2: prevention, prediction, personalization, psychological support, and participation, which could effectively improve clinical outcomes of patients. Based on RET mutations, MEN2 could be prevented through prenatal diagnosis or preimplantation genetic testing. Identification of pathogenic mutations in RET can enable early diagnosis of MEN2. Combining RET mutation testing with measurement of serum calcitonin, plasma or urinary metanephrine/normetanephrine, and serum parathyroid hormone levels could allow risk stratification and accurately prediction of MEN2 progression, thus facilitating implementation of personalized precision treatments to increase disease-free survival and overall survival. Furthermore, increased awareness of MEN2 is needed, which requires participation of physicians, patients, family members, and related organizations. Psychological support is also important for patients with MEN2 to promote comprehensive management of MEN2 symptoms. The “5P” strategies for management of MEN2 represent a typical clinical example of precision medicine. These strategies could effectively improve the health of MEN2 patient, and avoid adverse outcomes, including death and major morbidity, from MEN2.
Databáze: OpenAIRE